Chordia Therapeutics,Inc Logo

Chordia Therapeutics,Inc

Developing first-in-class, small-molecule anti-cancer drugs targeting RNA deregulation.

190A | T

Overview

Corporate Details

ISIN(s):
JP3283730004
LEI:
Country:
Japan
Address:
藤沢市村岡東2−26−1
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Chordia Therapeutics Inc. is a clinical-stage biotechnology company specializing in the research and development of innovative, first-in-class anti-cancer drugs. Established in November 2017 as a spin-out from a major pharmaceutical company, its mission is to deliver novel treatments to patients with unmet medical needs. The company focuses on developing a pipeline of small-molecule drug candidates that target RNA deregulation stress, a key factor in cancer development. Chordia Therapeutics operates with a focused R&D model, outsourcing activities such as manufacturing, distribution, and sales to external partners to advance its therapeutic programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 05:00
Registration Form
確認書
Japanese 8.1 KB
2025-11-21 05:00
Annual Report
有価証券報告書-第8期(2024/09/01-2025/08/31)
Japanese 2.6 MB
2025-09-05 08:30
Registration Form
有価証券届出書(参照方式)
Japanese 534.8 KB
2025-05-16 02:45
Major Shareholding Notification
臨時報告書
Japanese 20.2 KB
2025-04-11 04:50
Interim Report
半期報告書-第8期(2024/09/01-2025/08/31)
Japanese 144.4 KB
2025-04-11 04:50
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-12-17 07:30
Registration Form
訂正確認書
Japanese 8.7 KB
2024-11-29 07:37
Post-Annual General Meeting Information
臨時報告書
Japanese 23.1 KB
2024-11-29 07:36
Registration Form
確認書
Japanese 8.1 KB
2024-11-29 07:35
Governance Information
内部統制報告書-第7期(2023/09/01-2024/08/31)
Japanese 21.2 KB
2024-11-29 07:34
Annual Report
有価証券報告書-第7期(2023/09/01-2024/08/31)
Japanese 2.8 MB
2024-07-16 06:55
Quarterly Report
四半期報告書-第7期第3四半期(2024/03/01-2024/05/31)
Japanese 123.4 KB
2024-07-16 06:55
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-06-06 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB
2024-05-29 04:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB

Automate Your Workflow. Get a real-time feed of all Chordia Therapeutics,Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chordia Therapeutics,Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chordia Therapeutics,Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Neonode Inc. Logo
Licenses optical sensing and computer vision for HMI in automotive and consumer electronics.
United States of America
NEON
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France
ALNEV
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia
NFM
NexGen Energy Ltd. Logo
Uranium exploration company developing a high-grade mine to supply global clean energy fuel.
United States of America
NXE
Nexxen International Ltd. Logo
End-to-end programmatic ad platform for advertisers, agencies, & publishers, specializing in video & CTV.
United States of America
NEXN
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France
ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden
NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan
2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan
4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.